51
|
|
|
VPS33B interacting protein, apical-basolateral polarity regulator, spe-39 homolog |
C14orf133, SPE-39, SPE39, VIPAR, VPS16B, hSPE-39 |
|
52
|
|
|
Vasoactive intestinal peptide receptor 1 |
HVR1, II, PACAP-R-2, PACAP-R2, RDC1, V1RG, VAPC1, VIP-R-1, VIPR, VIRG, VPAC1, VPAC1R, VPCAP1R |
|
53
|
|
|
Vasoactive intestinal peptide receptor 2 |
C16DUPq36.3, DUP7q36.3, PACAP-R-3, PACAP-R3, VIP-R-2, VPAC2, VPAC2R, VPCAP2R |
|
54
|
|
|
Vitrin |
VIT1 |
Cerebral artery occlusion, Hypertrophic cardiomyopathy, Leprosy, Metabolic syndrome, Oligodendroglioma, Osteoarthritis, Ovarian serous carcinoma, Peripheral arterial disease, Schizophrenia, Stroke, Diabetes mellitus type 2, Upper aerodigestive tract neoplasm |
55
|
|
|
Vitamin K epoxide reductase complex subunit 1 |
EDTP308, MST134, MST576, VKCFD2, VKOR |
Aortic rupture, Blood coagulation disorder, Cerebrovascular disorder, Coronary artery disease, Coumarin resistance, Hemorrhage, Stroke, Thrombosis, Vascular disease, Venous thromboembolism, Combined vitamin k-dependent clotting factor deficiency |
56
|
|
|
Vitamin K epoxide reductase complex subunit 1L1 |
- |
|
57
|
|
|
Very low density lipoprotein receptor |
CAMRQ1, CARMQ1, CHRMQ1, VLDL-R, VLDLRCH |
Alzheimer disease, Autism, Autoimmune thrombocytopenic purpura, Breast cancer, Cerebellar ataxia, impaired intellectual development, and dysequilibrium, Cerebellar ataxia, intellectual disability, and dysequilibrium, Cerebellar hypoplasia, Cerebellar hypoplasia/atrophy, epilepsy, and global developmental delay, Congenital neurologic anomalies, Dysequilibrium syndrome, Intellectual developmental disorder, Nonalcoholic fatty liver disease, Obesity, Schizophrenia |
58
|
|
|
Vacuolar ATPase assembly factor VMA12 |
C17orf32, CDG2P, TMEM199, VPH2 |
|
59
|
|
|
Vacuolar ATPase assembly factor VMA21 |
MEAX, XMEA |
|
60
|
|
|
Vacuolar ATPase assembly factor VMA22 |
CCDC115, CDG2O, ccp1 |
|